nebaprubart   Click here for help

GtoPdb Ligand ID: 14574

Synonyms: JJP-1212 | JJP1212
Immunopharmacology Ligand
Compound class: Antibody
Comment: Nebaprubart (JJP-1212) is a potential first-in-class monoclonal antibody that targets Fc alpha receptor (FCAR; CD89).
Peptide sequence matches for the heavy and light chains of nebaprubart are claimed in patent US20230242646 [1]. In this patent, the most likely candidate to be nebaprubart is clone 10E7 humanized VL3 (VH3SQVL3).
Click here for help
No information available.
Summary of Clinical Use Click here for help
Nebaprubart (JJP-1212) was progressed as a clinical candidate for the treatment of IgA‑mediated conditions, including autoimmune and fibrotic diseases. See EU clinical trial 2023-508661-33-00. The EMA granted orphan medicinal product designation in October 2022, to treat linear IgA disease.